In one of two Great Debate sessions at ACR Convergence 2022 in Philadelphia, Pennsylvania, USA, two experts teamed up to provide opposing stands on whether now is the right time to be treating people at risk for rheumatoid arthritis in the preclinical stages of the condition in order to prevent disease onset.
Rituximab and cyclophosphamide have similar overall efficacy in patients with connective tissue disease-associated interstitial lung disease, but rituximab may be associated with fewer adverse events, suggest findings from a phase 2b trial.
Xenofon Baraliakos takes us through SURPASS, a phase 3b head-to-head trial that demonstrated equivalence of secukinumab versus adalimumab biosimilar in patients with radiographic axial spondyloarthritis.
Peresolimab, a PD-1 receptor agonist, may represent a promising approach to treating rheumatoid arthritis, with an “encouraging” safety profile, suggests research reported at the ACR Convergence 2022 in Philadelphia, Pennsylvania, USA.
A diet and exercise program delivered in community settings may improve some clinical outcomes for people with knee osteoarthritis and overweight or obesity, suggest findings from the WE-CAN pragmatic randomized controlled trial.